Advanced search
Publication Cover
Bioengineered Volume 10, 2019 - Issue 1
Submit an article Journal homepage
1,613
Views
4
CrossRef citations to date
0
Altmetric
Research Paper

Construction of Epstein-Bar virus cocktail peptide fused with Fcγ of IgG: as a potential delivery system for vaccine development

Saeid Amel Jamehdara Antimicrobial Resistance Research Center, Mashhad University of Medical Science, Mashhad, Iran
,
Samira Tabaeib Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
,
Baratali Mashkanic Department of Medical Biochemistry, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
,
Reza Karimid Department of Biology, Damghan Branch, Islamic Azad University, Damghan, Iran
,
Morteza Motallebnezhade Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran;f Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran;g Department of Immunology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran
&
Arezoo Esmailid Department of Biology, Damghan Branch, Islamic Azad University, Damghan, IranCorrespondence[email protected]
Pages 689-696 | Received 01 Jun 2019, Accepted 30 Oct 2019, Published online: 25 Nov 2019

References

  • Pourahamad M, Hooshmand F, Nezhad SO, et al. EBV seroepidemiology in married and unmarried women and men in Iran. Rep Biochem Mol Biol. 2014;2(2):94–97.
  • Farrell PJ. Epstein–Barr virus and cancer. Annu Rev Pathol. 2019;14:29–53.
  • Gurer C, Strowig T, Brilot F, et al. Targeting the nuclear antigen 1 of Epstein-Barr virus to the human endocytic receptor DEC-205 stimulates protective T-cell responses. Blood. 2008;112(4):1231–1239.
  • Andrei G, Trompet E, Snoeck R. Novel therapeutics for Epstein–barr virus. Molecules. 2019;24(5):997.
  • Wang ZH, Zhao JJ, Yuan Z. Lymphoepithelioma-like gastric carcinoma: A case report and review of the literature. World J Gastroenterol. 2016 14. 22(10):3056.
  • Chia W, Wang W, Teo M, et al. A phase II study evaluating the safety and efficacy of an adenovirus-ΔLMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma. Ann Oncol. 2011;23(4):997–1005.
  • Chen L, Luo C, Li N. Vaccines and antiviral drugs for diseases associated with the Epstein-Barr virus. INTECH Open Access Publisher; 2012.
  • Tabaei S, Mashkani B, Esmaili A, et al. Design of cocktail peptide vaccine against Cytomegalovirus infection. Iran J Basic Med Sci. 2016;19(4):449.
  • Pan J, Zhang Q, Zhou J, et al. Recombinant adeno-associated virus encoding Epstein-Barr virus latent membrane proteins fused with heat shock protein as a potential vaccine for nasopharyngeal carcinoma. Mol Cancer Ther. 2009;8(9):2754–2761.
  • Yang C, Gao X, Gong R. Engineering of fc fragments with optimized physicochemical properties implying improvement of clinical potentials for Fc-based therapeutics. Front Immunol. 2018;8;8:1860.
  • Gosselin EJ, Wardwell K, Gosselin DR, et al. Enhanced antigen presentation using human Fc gamma receptor (monocyte/macrophage)-specific immunogens. J Immunol. 1992;149(11):3477–3481.
  • Khanna R, Sherritt M, Burrows SR. EBV structural antigens, gp350 and gp85, as targets for ex vivo virus-specific CTL during acute infectious mononucleosis: potential use of gp350/gp85 CTL epitopes for vaccine design. J Immunol. 1999;162(5):3063–3069.
  • Lu L, Palaniyandi S, Zeng R, et al. A neonatal Fc receptor-targeted mucosal vaccine strategy effectively induces HIV-1 antigen-specific immunity to genital infection. J Virol. 2011;85(20):10542–10553.
  • Lima RT, Busacca S, Almeida GM, et al. MicroRNA regulation of core apoptosis pathways in cancer. Eur J Cancer. 2011;47(2):163–174.
  • Capone G, Fasano C, Lucchese G, et al. EBV-associated cancer and autoimmunity: searching for therapies. Vaccines (Basel). 2015;3(1):74–89.
  • Wang M, Jiang S, Liu X, et al. Expression, purification, and immunogenic characterization of Epstein–Barr virus recombinant EBNA1 protein in Pichia pastoris. Appl Microbiol Biotechnol. 2013;97(14):6251–6262.
  • Kato K, Sano H, Nagata K, et al. Synthetic peptides of Epstein-Barr virus-major envelope glycoprotein-350/220 do not prevent infection in a rabbit Epstein-Barr virus infection model. J Vaccines Vaccine. 2012;3:148.
  • Duraiswamy J, Burrows JM, Bharadwaj M, et al. Ex vivo analysis of T-cell responses to Epstein-Barr virus-encoded oncogene latent membrane protein 1 reveals highly conserved epitope sequences in virus isolates from diverse geographic regions. J Virol. 2003;77(13):7401–7410.
  • Guyre PM, Graziano RF, Goldstein J, et al. Increased potency of Fc-receptor-targeted antigens. Cancer Immunol Immunother. 1997;45(3–4):146–148.
  • Vieira Gomes A, Souza Carmo T, Silva Carvalho L, et al. Comparison of yeasts as hosts for recombinant protein production. Microorganisms. 2018;6(2):38.
  • Gidijala L, Uthoff S, van Kampen SJ, et al. Presence of protein production enhancers results in significantly higher methanol-induced protein production in Pichia pastoris. Microb Cell Fact. 2018;17(1):112.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.